On September 9, a federal appeals court in the Fifth Circuit reviewed Louisiana's status in the mifepristone case. This state, which has an almost complete abortion ban, is seeking to reinstate previous laws for the national distribution of mifepristone; a medication that patients can currently receive through telehealth services and mail.
Concerns of the State of Louisiana
Louisiana claims that mifepristone can lead to serious complications such as severe bleeding and life-threatening infections, and is asking the FDA to reinstate the pre-2023 law that required in-person distribution at clinics, offices, or hospitals. The state of Louisiana believes that changes made during the Biden administration have somehow weakened its abortion ban.
In May, a panel from the Fifth Circuit Court of Appeals temporarily blocked this law, but in the same month, the Supreme Court overturned that order and continued the distribution of the drug by mail. Currently, the FDA, under Donald Trump's presidency, is reviewing safety claims regarding this drug.
Legal Challenges and Pressure on Mifepristone
If Louisiana succeeds in this lawsuit against the FDA and reinstates the in-person distribution requirement, the demand for medical abortions, which now constitutes a significant portion of abortions in the United States, may sharply decline. This is because patients would have to overcome more barriers to obtain this medication.
The Attorney General of Louisiana, Jeff Landry, told the new three-judge panel of the appeals court on September 9 that the FDA's law undermines the abortion bans that were enacted after the Supreme Court's overturning of Roe v. Wade. He noted that "there is no doubt that Louisiana receives about 1,000 abortions monthly due to mifepristone."
The judges continued to examine Louisiana's status with questions about the state's legal right to sue regarding the FDA's decision. Can this state really demonstrate that the abortions performed in it are related to this new law?
Despite mifepristone still reaching Louisiana, legal challenges and social pressures on this drug are increasingly rising. The future of this drug and its distribution in the states is under close scrutiny, and the outcome of this lawsuit could have profound impacts on women's rights and abortion status in America.
